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The Journal of Immunology
Aging Converts Innate B1a Cells into Potent CD8+ T Cell
Inducers
Catalina Lee-Chang,*,†,‡ Monica Bodogai,* Kanako Moritoh,* Xin Chen,x,{
Robert Wersto,‖ Ranjan Sen,# Howard A. Young,{ Michael Croft,** Luigi Ferrucci,†† and
Arya Biragyn*
B cell dysregulation in aging is thought to mostly occur in conventional B2 cells without affecting innate B1 cells. Elderly humans
and mice also accumulate 4-1BBL+ MHC class-IHi CD86Hi B cells of unknown origin. In this article, we report that these cells,
termed 4BL cells, are activated murine and possibly human B1a cells. The activation is mediated by aging human monocytes and
murine peritoneal macrophages. They induce expression and activation of 4-1BBL and IFN-gR1 on B1a cells to subsequently
upregulate membrane TNF-a and CD86. As a result, activated B1a/4BL cells induce expression of granzyme B in CD8+ T cells by
targeting TNFR2 via membrane TNF-a and providing costimulation with CD86. Thus, for the first time, to our knowledge, these
results indicate that aging affects the function of B1a cells. Upon aging, these cells lose their tumor-supporting activity and become
inducers of potentially antitumor and autoimmune CD8+ T cells. The Journal of Immunology, 2016, 196: 3385–3397.
T
he immune system becomes dysregulated upon aging
in mammals, and this dysregulation affects both myeloid
and lymphoid immune cell compartments (see reviews
in Refs. 1, 2). Aging-associated intrinsic and extrinsic factors
skew hematopoiesis toward myelopoiesis (3, 4), resulting in reduced
B cell–committed progenitors in bone marrow (BM) (5–7)
and changes in the prevalence and function of myeloid cells
and lymphocytes in circulation and in tissues. For example, the
elderly accumulate monocytes and macrophages expressing pro-
inflammatory cytokines such as TNF-a and IFN-g (8, 9) and,
in mouse peritoneum, M1 macrophages expressing reactive oxy-
gen (10). Aging also impairs phagocytosis of human peripheral
blood (PB) CD14+ monocytes, murine neutrophils, and peritoneal
cavity (PC) macrophages (8, 11, 12). Compounded with a lifelong
antigenic exposure, changes in T cells, and increased half-life of
mature B cells (13, 14), B cells subsequently become enriched for
Ag-experienced memory and mature conventional B2 cells at the
expense of naive B cells (15–18). In contrast, little is known
whether aging affects innate B1a cells, the key producers of nat-
ural Abs to pathogens and endogenous Ags. Although the capacity
to generate B1 cells is reduced in BM after birth (19), aging does
not appear to affect their generation in BM of mice (20) and even
increases their frequency in PC and spleen of old mice (11, 21).
B1 cells differ from B2 cells by a distinct cellular origin, such as
the generation from specific fetal progenitors and a limited self-
renewing capacity, and by their preferential localization in the
coelomic cavity, Peyer’s patches, and tonsils (22–25). They also
represent ,5% of B cells in circulation and in the peripheral
lymphoid tissues of young adult mice (22, 25). Murine B1 cells
consist of CD5+(B1a) and CD52(B1b) CD11b+ B cells (25),
whereas their human counterparts remain poorly characterized
(26–28) but have been shown to be a subset of memory CD27+
CD43+CD692CD20+ B cells (27). Aging mice also accumulate
CD232 CD21/CD352B cells (so-called aging-associated B cells,
ABCs) refractory to BCR and CD40 engagement (29). Recently,
we reported that aging humans, macaques, and mice also accu-
mulate another type of CD19+ B cells of unknown origin. These
cells, designated 4BL cells, express high levels of HLA-I, the
costimulatory molecule CD86, and a TNF superfamily type 2
transmembrane protein 4-1BBL/CD137L (30). Although macro-
phages and dendritic cells (DC) express 4-1BBL (31), it can be
transiently expressed on B cells upon a combined stimulation of
BCR and CD40 (32). This cell-surface molecule receives and
transmits signals upon engagement with its receptor 4-1BB/
CD137 expressed on activated NK and T cells and splenic DCs
(31, 32), resulting in activation of cytolytic CD8+ T cells and NK
cells (33–36). In synergy with B7 and ICAM, 4-1BBL can also
induce proliferation of naive CD4+ T cells when Ag is limiting
(37). We have reported that, by using the 4-1BBL/4-1BB and
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MHC class-I/TCR signaling pathways, 4BL cells also induce the
generation of Ag-specific perforin+ GrB+ CD8+ T cells (30). In
fact, this feature of 4BL cells explains the enrichment of highly
differentiated GrB+CD45RA+CD8+ T cells in aging humans (15)
and accounts for a paradoxical retarded growth of poorly immu-
nogenic tumors in the elderly (30).
In this article, we report that murine B1a cells, and possibly
human B1 cells, become converted into 4BL cells upon aging.
Surprisingly, the conversion is not due to intrinsic changes in aging
B cells, but instead is induced by myeloid cells of aging subjects,
such as human PB monocytes and murine peritoneal macrophages.
First, they induce BCR and CD40 signaling that leads to expression
of 4-1BBL, IFN-gR1, and membrane TNF-a (mTNF-a) in B1a
cells. Then, upon engagement of 4-1BBL and IFN-gR1 with their
respective stimuli (4-1BB and IFN-g also provided by aging my-
eloid cells), B1a cells further upregulate expression of mTNF-a
and CD86. The resulting 4BL cells then use mTNF-a in the in-
duction of GrB expression in CD8+ T cells by targeting TNFR2
while providing costimulation with CD86. Overall, our results
reveal for the first time, to our knowledge, a unique functional
consequence of the cross talk between dysregulated myeloid and
lymphoid cell compartments upon aging. This process converts
innate B1a cells from presumably being immunosuppressive cells
into the inducers of cytolytic GrB+CD8+ T cells.
Materials and Methods
PBMCs were collected from PB of elderly (n = 19, age6 SD: 796 6.45 y)
and young (n = 11, age 6 SD: 41 6 7.2 y) healthy humans from the
Baltimore Longitudinal Study of Aging (National Institute on Aging
[NIA]) under the Human Subject Protocol 2003054 and Tissue Procure-
ment Protocol 2003-076. Young (5–8 wk) female C57BL/6j and BALB/c,
congenic JHT mice with B cell deficiency (B6.129P2-Igh-Jtm1Cgn/J) and
GFR+ mice [C57BL/6-Tg(UBC-GFP)30Scha/J] were from The Jackson
Laboratory (Bar Harbor, ME), and 4-1BBL and 4-1BB–knockout (KO)
mice (4-1BBL KO and 4-1BB KO) were reported elsewhere (33, 38). Old
mice (18–22 mo old) were from Aged Rodent Colony, NIA. ARE-Del mice
(39) and TNF-a, TNFR1, TNFR2, and IFN-gR KO mice were from the
National Cancer Institute (NCI)-Frederick, MD.
Flow cytometry
All Abs were from Biolegend (San Diego, CA) except otherwise specified.
Human cell Fc receptors were blocked using Human TruStain FcX 5 min
before staining with Abs, such as anti-human Ab: TNF-a–allophycocyanin
(BD Pharmingen, Piscataway, NJ) or –FITC (clone MAb11), IFN-g–FITC
(BD Pharmingen) or –Pacific blue (clone 4S.B3), CD19-PerCP/Cy5.5
or –Alexa Fluor 780 (clone HIB19), 4-1BBL-PE or -allophycocyanin
(5F4), CD86-PE (clone FUN-1; BD Pharmingen), CD27-PerCP/Cy5.5
(clone M-T271), CD119 (IFN-gR a-chain)-PE or -Biotin (clone GIR-
208), streptavidin-Pacific blue or –allophycocyanin, IL-10–PerCP/
Cy5.5 (JES3-9D7), CD14–Pacific blue (clone M5E2) or -FITC (clone
HCD14), CD3-PE (clone SP34; BD Pharmingen), CD8-allophycocyanin
or -PE (clone HIT8a), GrB-FITC (clone GB11), CD11b-FITC or –Alexa
Fluor 700 (clone M1/70), CD138-PECy7 (clone DL101; eBioscience),
CD43-allophycocyanin (clone eBio 84-3C1; eBioscience), CD69-
allophycocyanin-Cy7 (clone FN50; BD Pharmingen), and CD120b
(TNFR2)-PE (clone 3G7A02). For murine cells phenotype analysis, cells
were preincubated with Tru Stain FcX before immunostaining with dif-
ferent combinations of the following anti-mouse Ab: TNF-a–FITC (clone
MP6-XT22), 4-1BBL–PerCP–eFluor710 (eBioscience) or -PE (clone
TKS-1), CD5-PerCP/Cy5.5 (eBioscience), -FITC or -allophycocyanin
(clone 53-7.3), CD119 (IFN-gR a-chain)-Biotin (clone 2E2), streptavidin–
Pacific blue or -allophycocyanin, CD19–allophycocyanin–eFluor 780
(clone 1D3; eBioscience) or -PerCP/Cy5.5 or -allophycocyanin (clone
6D5), CD86-PerCP/Cy5.5 (clone GL-1), CD23-FITC (clone B3B4; BD
Pharmingen), CD21/CD35-allophycocyanin (clone 7G6), CD93-PeCy7 or
-FITC (clone AA4.1), CD1d-PE or –Pacific blue (clone 1B1), CD120b
(TNFR2)-PE (clone TR75-89), CD8-allophycocyanin (clone 53-6.7). For
intracellular cytokine staining, freshly isolated human PBMCs or murine
cells were activated with PMA (5 ng/ml; R&D, Minneapolis, MN) +
Ionomycin (500 ng/ml; R&D) and brefeldin A (1/1000; eBioscience) for
5 h at 37˚C. The cells were stained using the Intracellular Fixation and
Permeabilization Buffers Kit (eBioscience) following the manufacturer’s
protocol. Appropriate isotype controls were used throughout all experi-
ments.
In vitro assays
B cells from human PB and murine spleens were negatively isolated using
B-Cell Isolation Kit II ($98% purity; Miltenyi Biotec, Auburn, CA) and
the EasySep Mouse B Cell Isolation Kit ($95% purity; STEMCELL
Technologies, Vancouver, BC), respectively. 4-1BBL–expressing B cells
(named as 4BL cells) were magnetically sorted using anti–4-1BBL–PE
(human: clone 5F4; mouse: clone TKS-1; both from Biolegend) + anti-PE
MicroBeads (Miltenyi Biotec). CD8+ T cells were isolated negatively
using the Human CD8+ T Cell Isolation Kit or Mouse CD8a+ T Cells
Isolation Kit ($97% purity; Miltenyi Biotec). The B cell–mediated acti-
vation of CD8+ T cells was performed as previously reported (30). In brief,
young subject CD8+ T cells were labeled with eFluor 450 cell proliferation
dye (10 min at 37˚C, 5 mM; eBioscience) and mixed with respective
syngeneic (murine) or allogeneic (human) B cells from young and aging
subjects at 1:1 ration in the presence of 1.5 mg/ml anti-CD3 Ab (UCHT1
and HIT3a clones, respectively, for human and murine cells; BD Phar-
mingen) for 4–5 d in complete RPMI at 37˚C in humidified atmosphere
with 5% CO2. To test the function of TNF-a/TNFR2 axis in induction of
GrB+CD8+ T cells, we used B cells and CD8+ T cells from TNF-a and
TNFR2-deficient congenic mice, respectively. Alternatively, wild type
(WT) cells were incubated with 5 mg/ml TNF-a blocking Ab with murine
(clone MP6-XT22, Rat IgG1k; eBioscience) or human cells (clone MAb-1,
Mouse IgG1k; eBioscience), or human CD8+ T cells were pretreated 10 min
at room temperature with 10 mg/ml anti-human TNFR2 blocking Ab (clone
hTNFR-M1, Rat IgG2b; BD Pharmingen) before mixing with B cells. To
test the importance of cell contact, we performed a transwell assay in a 24-
well tissue plate (3-mm pore size; Corning Life Science, Acton, MA). To test
the role of CD86 function, murine 4BL cells were pretreated with 10 mg/ml
anti-CD86 Ab (clone PO3.1; eBioscience) or isotype control (Rat IgG2b, k;
eBioscience) at room temperature before mixing at 1:1 ratio with eFluor
450–labeled CD8+ T cells and 1.5 mg/ml soluble anti-mouse CD3.
Induction of TNFR2 expression on human CD8+ T cells was evaluated
after 24-h activation with beads coupled with anti-CD3/CD28 or anti-CD3/
CD28/CD137 Abs at 1:30 bead/cell ratio (Invitrogen), or with soluble anti-
CD3 (1.5 mg/ml, clone HIT3a; BD Pharmingen) and anti-CD28 (1.5
mg/ml, clone 37.51; BD Pharmingen) and 4-1BB agonistic 3H3 Ab as
described elsewhere (40). Alternatively, 4-1BBL+ B cells were cultured
overnight with eFluor 450–labeled CD8+ T cells from young mice at a 1:1
ratio in the presence of 1.5 mg/ml soluble anti-CD3 Ab. 4-1BBL and IFN-
gR1 upregulation in murine splenic B cells (2 3 106/ml) was induced with
10 mg/ml IgM [AffiniPure F(ab9)2 Fragment Goat anti-mouse IgM; Jack-
son Laboratories] and 5 mg/ml anti-mouse CD40 agonistic Ab (FGK45;
ENZO Lifesciences) by treatment for 18 h. CD86 was induced by treating
B cells with 100 U/ml IFN-g (R&D) for 18 h. To evaluate the effect of
4-1BBL ligation on TNF-a induction, we stimulated cells with LPS
(1 mg/ml), plate-bound 4-1BB:Fc fusion protein (R&D), or control Ab
(human IgG1; R&D) in 96 flat-bottomed plates for 24 h at 37˚C.
4BL cell induction by myeloid cells
PB monocytes (isolated using the Human Monocyte Isolation Kit II;
Miltenyi Biotec) or murine PC myeloid (depleted of B, T, and NK cells
treated with mixture of anti-mouse CD19-PE, CD3-PE, and DX5-PE Abs
and anti-PE MicroBeads; Miltenyi Biotec) were mixed with eFluor 450–
labeled (5 mM; eBioscience) B cells from respective young subjects at a
1:1 ratio. To block BCR signaling, we pretreated B cells with Bruton’s
tyrosine kinase (Btk; 20 nM, PC1-32765; Selleckchem, Boston, MA) and
SYK (4 mM, R406; Selleckchem) inhibitors for 30 min at 37˚C before
mixing with myeloid cells. CD40 signaling was blocked with anti-mouse
CD40L blocking Ab (10 mg/ml, clone MR1; eBioscience).
Ag-specific induction of CD8+ T cells by 4BL cells
Young (10-wk-old) and old (21-mo-old) C57BL/6 mice were either s.c.
challenged with B16 melanoma cells as described elsewhere (41) or i.p.
injected with 3 mg/ml albumin from chicken egg white (Sigma-Aldrich, St.
Louis, MO) in 200 ml PBS, to test whether naive 4BL cells can process and
present self-Ag. After 4 d, the mice were euthanized and splenic B cells
were isolated with the EasySep Mouse B Cell Isolation Kit ($95% purity;
STEMCELL Technologies). Cells were further separated into CD5+ and
CD52 B cells using anti-mouse CD5-PE (clone 53-7.3) and anti-PE
MicroBeads. Alternatively, peritoneal cavity B cells were depleted of
CD23+ cells using anti-mouse CD23-PE (clone B3B4; Biolegend) and
anti-PE MicroBeads. CD19+ B cells were then positively selected using
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anti-mouse CD19-PE (clone 6D5) and anti-PE MicroBeads (.98% pu-
rity). B cells were enriched with 70–90% B1a cells according to CD11b
and CD5 staining. To prepare target CD8+ T cells, we s.c. immunized 8- to
11-wk-old female pmel and OT-1 mice with gp10025–33– or OVA257–264–
specific TCR-transgenic CD8+ T cells, respectively, with 10 mg human
gp10025–33 peptide or 5 mg OVA257–264 peptide (SIINFEKL; ANASpec) in
IFA. After 4–5 d, splenic CD8+ T cells from immunized mice were isolated
using the EasyStepMouse CD8+ T Cell Enrichment Kit (STEMCELL
Technologies) and labeled with eFluor450 cell proliferation dye (eBio-
science). Then, to test for B cell–induced activation of CD8+ T cells, we
cultured the eFluor450+ CD8+ T cells from pmel and OT-1 mice with
B cells from young or old WT mice challenged with B16 melanoma or
OVA protein, respectively, at 1:1 ratio for 5 d in complete RPMI without
any stimulation.
In vivo manipulations
Animals were housed in a pathogen-free environment at the National In-
stitute on Aging Animal Facility (Baltimore, MD) under the Guide for the
Care and Use of Laboratory Animals (National Institutes of Health [NIH]
Publication No. 86-23, 1985). For adoptive transfer experiments, 5 3 106
eFluor 450–labeled B cells from spleens and PC of young WT or GFP-
transgenic mice were injected (i.v. or i.p.) into congenic old and young
mice to evaluate PC B cells after 5–6 d. PC macrophages were depleted in
old mice by two i.p. injections of 150 ml clodronate liposomes (Chlo-
phosome) 2 d before B cell transfer. The generation of Old-restored mice
(i.e., induction of new B cell lymphopoiesis in old mice treated with anti-
CD20 Ab) was described elsewhere (30). B1a cells and follicular B (FOB)
cells were magnetically or FACS sorted from C57BL/6 mice and i.v. in-
jected (2 3 106 cells) into JHT mice 1 d after s.c. challenge with B16-F10
melanoma cells (105 in 100 ml PBS; American Type Culture Collection).
Statistical analysis
The results are presented as the mean 6 SEM, and significance was
assessed by Mann–Whitney and nonparametric test (Prism 6; GraphPad
Software, San Diego, CA). A p value ,0.05 was considered statistically
significant.
Results
Aging milieu activates innate B1a cells
We previously observed that the reappearance of 4BL cells after
transient B cell depletion in old mice (Old-restored) is delayed for
1 mo compared with the rest of the B cells (M. Bodogai and
A. Biragyn, personal communication, and Ref. 30), and that cancer
patients also accumulate 4BL cells upon autologous hematopoi-
etic stem cell transfer (30). These data suggest that the generation
of 4BL cells could be induced by extrinsic factors. To test this
possibility, we injected splenic B cells of young GFP-expressing
mice into the PC of 18-mo-old and 8- to 10-wk-old congenic mice
(old and young, respectively, n = 6/group; Supplemental Fig. 1Ai).
After 6 d, mice were euthanized to evaluate PC B cells. The in-
jected GFP+ B cells markedly induced expression of 4-1BBL in
old, but not young, mice (p , 0.01; Fig. 1Ai), indicating that
aging milieu induces 4BL cells. The 4-1BBL+GFP+ B cells also
upregulated TNF-a (both intracellular and membrane forms; Fig.
1Aii, 1iii) and surprisingly expressed CD5 (p , 0.05; Fig. 1Aiv).
Because CD5 defines murine B1a cells (23–25), they could be the
source of 4BL cells upon aging. To test this possibility, we re-
peated the experiment by i.p. injecting a separate group of young
and old mice with GFP+ B cells isolated from PC (instead of
spleen) of young mice. Compared with splenic B cells, PC GFP+ B cells
induced markedly higher levels of 4-1BBL and mTNF-a in
aging mice (Supplemental Fig. 1Aii–iv). We also detected 4-
1BBL+TNF-a+CD5+GFP+ B cells in PC and spleens of old mice
injected via tail vein (Supplemental Fig. 1B). Importantly, host PC
B cells (GFP2) were markedly enriched for 4-1BBL+TNF-a+
CD5High B cells in old mice (p , 0.005 as compared with young
mice; Fig. 1B). To further implicate B1a cells in the conversion,
we analyzed PC B cell subsets and found that CD5+ pro-B10 cells
[which generate regulatory B10 cells (42)] and CD52B cells were
only marginally positive (,2%) for 4-1BBL and TNF-a regard-
less of the age of mice (Fig. 1C, Supplemental Fig. 1C). We also
tested whether the increase of 4-1BBL+TNF-a+ B cells is due to
proliferation of pre-existing 4BL cells. Upon adoptive transfer of
eFluor 450–labeled B cells into PC of old and young mice, we
did not detect dilution of eFluor 450 even 6 d after injection
(Supplemental Fig. 1D). Thus, the aging milieu mostly activates
B1a cells without expanding their pre-existing 4BL cell subsets.
Next, to further link the activated B1a cells with 4BL cells, we
tested whether they can induce the generation of cytolytic
CD8+ T cells expressing GrB [the key function of 4BL cells (30)].
Sort-purified B cells (B-total), pro-B10, and B1a cells from PC of
old and young mice were in vitro–cocultured with young mouse
eFluor 450–labeled CD8+ T cells stimulated with anti-CD3 Ab for
5 d. Although anti-CD3 Ab stimulation induced proliferation of
CD8+ T cells, that is, the cells comparably diluted eFluor 450 re-
gardless of the B cells or age of the mice (Supplemental Fig. 1E),
old mouse B cells per se induced greater GrB expression in
CD8+ T cells compared with young mouse B cells (B-total: 22.8 6
0.42 versus 10.5 6 0.42% and pro-B10: 14 6 0.27 versus 6.2 6
0.29%, respectively, old versus young, p# 0.05; Fig. 1D). However,
compared with young or old mouse B-total cells or even pro-B10
cells, B1a cells of old mice induced significantly higher levels of
GrB+CD8+ T cells (45 6 4.4 versus 12.8 6 0.23%, respectively,
old versus young, p , 0.05; Fig. 1D). Hence B1a cells can indeed
become 4BL cells in aging mice. To test whether there is a similar
conversion in humans, we compared PB of young (,50 y of age,
n = 11) and old (.75 y old, n = 19) healthy donors. The fre-
quency of 4-1BBL+TNF-a+ memory (CD27+CD432) and B1 cells
(CD27+CD43+CD692CD20+) (27) was increased in the elderly
(Supplemental Fig. 1F). (Note: The definition of human B1a cells
remains unclear, and thus we evaluated only B1 cells usually
found within memory B cells in PB.) As in mice, the 4BL cells of
elderly people expressed higher levels of mTNF-a than 4-1BBL2
B cells (p , 0.01) and 4BL cells of young donors (p , 0.05; Fig.
1E). In the MLR assay with allogeneic CD8+ T cells of young
people, 4BL cells within memory CD27+ B cells of the elderly
induced higher levels of GrB expression in CD8+ T cells compared
with unsorted B cells (B-total) or 4BL cells of young donors (p #
0.05; Fig. 1F, Supplemental Fig. 1G).
Aging converts splenic B1a cells into 4BL cells and disables
their tumor-supporting activity
Although B1a cells represent ,5% of B cells in spleens of young
adult mice (22, 25), their conversion into 4BL cells probably
explains the induction of GrB+CD8+ T cells that we previously
linked with the splenic B cells of aging mice (30). To test this
possibility, we analyzed expression of 4-1BBL in various subsets
of splenic B cells. 4-1BBL was increased in aging marginal zone
B, FOB cells, and ABCs, but the increase only reached the level of
sB1a cells of young mice (Fig. 2A). In contrast, aging markedly
upregulated 4-1BBL in sB1a cells (17.23 6 0.67 versus 5.39 6
1.62%, respectively, old versus young, p , 0.001; Fig. 2A),
suggesting that they become 4BL cells. To further confirm this
possibility, we tested the function of sB1a cells and FOB cells of
young and old mice in a 5-d GrB+CD8+ T cell induction assay (as
used earlier). Note that ABCs were not tested here because they do
not function as 4BL cells (30). Aging mouse sB1a cells strongly
induced expression of GrB in CD8+ T cells, whereas young mouse
sB1a cells or FOB cells of young or old mice failed to do so
(Fig. 2B). To confirm this finding, we also tested sB1a cells from
Old-restored mice, the old mice whose 4BL cells were reduced
despite the restoration of the B cell compartment after depletion of
B cells with anti-CD20 Ab (30). Compared with control old mice
The Journal of Immunology 3387
 
treated with an irrelevant IgG (Old-IgG), B cells of Old-restored
mice contained fewer 4-1BBL+sB1a cells (Fig. 2A) and could not
efficiently induce GrB+CD8+ T cells (p , 0.05; Fig. 2B).
A consequence of 4BL cell enrichment in mice is that it retards
growth of poorly immunogenic B16 melanoma cells (30). Thus, to
test the in vivo function of sB1a cells, we adoptively transferred
B cell–deficient JHT mice (JHT mice) with sB1a or FOB cells sort-
purified from congenic naive young or old mice. Then the mice
were s.c. challenged with a lethal dose of B16 melanoma cells
(Fig. 2C). Transfer of FOB cells and, in particular, sB1a cells of
young mice significantly increased growth of the B16 melanoma
(p , 0.05; Fig. 2C, 2D), confirming their tumor-supporting
functions (43, 44). In contrast, the transfer of sB1a cells of old
mice failed to do so and instead retarded tumor growth (p , 0.05
compared with mock treatment; Fig. 2C, 2D). This response was
lost if sB1a cells were from Old-restored mice, as the tumor grew
as fast as after the transfer of young sB1a cells (Fig. 2C, 2D). The
JHT mice replenished only with aging sB1a cells contained high
levels of GrB+CD8+ T cells in the circulation (Fig. 2E) and in the
secondary lymphoid organs (Supplemental Fig. 1H), whereas
transfer of sB1a cells of Old-restored or young mice failed to
increase those cells (Fig. 2E, Supplemental Fig. 1H). This result
corroborates our previous finding that 4BL cells retard B16 mel-
anoma growth by inducing antitumor GrB+CD8+ T cells (30),
suggesting that aging B1a cells became potent inducers of Ag-
specific GrB+CD8+ T cells. We tested this possibility using TCR-
FIGURE 1. The aging milieu activates B1a cells. (A and B) Young and old C57BL/6 WT mice were i.p. injected with 5 3 106 splenic B cells from
congenic GFP+ young mice. Frequency (dots) and mean value (lines) of 4-1BBL+ in GFP+ B cells (Ai and Aiv) and host GFP2B cells (Bi) coexpressing
TNF-a (Aii), mTNF-a (Aiii and Bii), and CD5 (Aiv) in PC of each mouse after 6 d, as indicated in the y-axis. Results are from three to four mice/group, and
experiments were reproduced three times. (C) PC CD5+ B cells of old mice mostly express 4-1BBL and TNF-a. Arrows indicate the B cell population
tested (center panel). (D) Aging PC B1a cells mostly induce GrB+CD8+ T cells. Unsorted B cells (B-total) and FACS-sorted pro-B10 (pro-B10) and B1a B
(B1a) cells from PC of young and old mice were cultured for 4–5 d with eFluor 450–labeled CD8+ T cells stimulated with 1.5 mg/ml anti-mouse CD3 Ab. A
representative dot plot (Di) of a summary graph [mean 6 SEM, (Dii)] of two independent experiments performed in triplicate. (E) Elderly human 4-1BBL+
B cells express high levels of TNF-a. Frequency mean 6 SEM of TNF-a+ in 4-1BBL2 and 4-1BBL+ B cells in young and elderly people PB after PMA/
Ionomycin/brefeldin A activation. (F) 4-1BBL+ B cells (4BL cells) from elderly people induce higher levels of GrB+CD8+ T cells. Frequency mean6 SEM
of a representative result reproduced with five old and five young human cells. *p , 0.05, **p , 0.01.
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transgenic CD8+ T cells from pmel and OT-1 mice, which recog-
nize gp10025–33 peptide [of a pigment synthesis Ag expressed by
B16 melanoma cells (45)] and OVA257–264 peptide, respectively.
First, we in vivo–primed B cells with an Ag by challenging young
and old WT C57BL/6 mice with B16 melanoma or i.p. injecting
200 ml OVA (intact protein, 3 mg/ml). Then, after 4–5 d, B cells
were isolated and cocultured with respective TCR-transgenic
CD8+ T cells for 5 d without any cognate Ag or anti-CD3 Ab
stimulation. Control B cells from naive or mock-treated mice did
not activate CD8+ T cells, verifying that their activation requires a
cognate Ag presentation (Fig. 2F, 2G). In contrast, splenic CD5+
B1 cells and, in particular, PC B1 cells of old mice with B16
melanoma, but not splenic CD52 B cells of old mice or B cells
and B1a cells of young mice, markedly induced proliferation of
pmel CD8+ T cells (Fig. 2F). Similarly, B1 cells of OVA-injected
WT mice also activated OT-1 CD8+ T cells, which was more
FIGURE 2. Aging splenic B1a cells express 4-1BBL (A), induce GrB+CD8+ T cells (B), and reduce tumor growth (C). The 4-1BBL+ subset (left panel)
within splenic mature B-cell subsets (CD932CD19+) and their ability to induce GrB+CD8+ T cells (B) as in Fig. 1. Y-axis, frequency mean 6 SEM of three
independent experiments performed in triplicate with B cells sort-purified from young (dark bars), old (Old-IgG, open bars), and old mice with a restored B
cell compartment (Old-restored, light gray bars). Sort-purified FOB cells and sB1a cells of young, Old-restored mice (Old-restored), or old mice pretreated
with control IgG (Old-IgG) were transferred into B cell–deficient JHT mice with B16 melanoma to test their ability to affect growth (C) and weight (D) of
tumor and generate GrB+CD8+ T cells at day 20 after tumor challenge (E). Experiment was reproduced twice with four to five mice per group. (F and G)
Aging B1a cells induce Ag-specific GrB+CD8+ T cells by presenting endogenous Ags. Sort-purified CD52 and CD5+ splenic B cells or CD23-depleted PC
B cells (B1) from old and young C57BL/6 mice either with B16 melanoma or i.p. injected OVA protein were cultured for 5 d with TCR transgenic
CD8+ T cells from young pmel (F) or OT-1 mice (G), respectively. (F and G) No exogenous Ag or anti-CD3 Ab stimulation was used during B cell and T cell
coculture; the TCR transgenic T cells were preactivated in pmel and OT-1 mice for 5 d by s.c. injection of 5 mg of a respective peptide in IFA. Mean (%) 6
SEM of three mice per group experiment (F) and individual mice (G).*p , 0.05, **p , 0.01, ***p , 0.005.
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pronounced for aging B1 cells (Fig. 2G). Thus, aging B1a cells
can induce Ag-specific CD8+ T cell responses.
Myeloid cells induce the generation of 4BL cells
To understand the mechanism of the 4BL cell induction, we treated
B cells of young mice with PC lavage of old mice. It did not induce
4BL cells (not depicted). Thus, given that BCR/CD40 stimulation
upregulates (albeit transiently) expression of 4-1BBL on B cells
(32), the induction is probably mediated by PC cells. To test
this possibility, we first confirmed the upregulation of 4-BBL on
young mouse B cells upon stimulation with anti-IgM/CD40 Ab
(Fig. 3Ai). The stimulated B cells also induced higher levels of
GrB+CD8+ T cells in our in vitro induction assay (p , 0.05;
Fig. 3Aii). However, this induction was lost if B cells were from
4-1BBL–deficient (KO) mice (Fig. 3Aii), underscoring the im-
portance of 4-1BBL (30). Because the BCR/CD40 signaling can
be triggered by macrophages (46, 47) dysregulated upon aging (8),
we also evaluated CD11b+ myeloid cells and macrophages in PC
of old and young mice. These cells expressed higher levels of
CD40L (needed for CD40 signaling) and IFN-g in PC of aging
mice compared with young mice (Supplemental Fig. 2A–F). To
test their function, we in vitro–cocultured CD11b+ cells purified
from PC of young or old mice (respectively, Young-M and Old-M,
.70% pure after depletion of T, NK, and B cells; Supplemental
Fig. 3A) with eFluor 450–labeled PC CD5+ B cells of young mice.
Upon overnight coculture, the Old-M, but not Young-M, cells
strongly upregulated expression of 4-1BBL in B1a cells (p ,
0.005; Fig. 3B). Because the CD5+ B cells failed to dilute eFluor450
even after 5–6 d of coculture (Supplemental Fig. 3B), Old-M cells
induced conversion of 4BL cells without expansion of pre-existing
4-1BBL+B1a cells. Next, to link the fact that induction requires
BCR/CD40 signaling, we repeated the experiment by cocultur-
ing Old-M cells with B1a cells in the presence of anti-CD40L
blocking Ab or with B1a cells pretreated with spleen tyrosine
kinase (Syk) or Btk inhibitors, which inactivate BCR signal-
ing (48). Both treatments completely disabled the induction of
4-1BBL+B1a cells (p, 0.05; Fig. 3B), indicating the importance of
the BCR/CD40 signaling axis. To confirm the importance of aging
myeloid cells in vivo, we modified the experiment shown in Fig.
1A by transferring young mouse GFP+ B cells into congenic old
mice treated with clodronate liposomes to deplete macrophages.
Although control macrophage-sufficient old mice significantly
increased the frequency of 4-1BBL–expressing CD5+GFP+ B cells
(p = 0.02; Fig. 3C, see also Fig. 1A), the macrophage-depleted old
mice failed to do so just as observed in young mice (Fig. 3C).
Thus, the conversion of B1a cells into 4BL cells is, at least in part,
mediated by macrophages of aging mice. To test whether a similar
induction occurs in human 4BL cells, we cocultured overnight PB
FIGURE 3. PC myeloid cells induce the generation of 4BL cells. Resting B cells of young mice upregulate 4-1BBL upon overnight stimulation with anti-
mouse IgM (Fab, 10 mg/ml) and CD40 agonistic Ab (Ai, 5 mg/ml) or with myeloid cells from PC of old, but not young, WT mice (B). Upregulation was
associated with the ability to induce GrB+CD8+ T cells if B cells were from WT but not 4-1BBL KO mice (Aii). Myeloid cells cannot induce 4-1BBL+ B
cells if B cells were pretreated with Btk (20 nM) or SYK (4 mM) inhibitors, or stimulated in the presence of CD40 blocking Ab (B). (C) Clodronate
liposome–induced depletion of phagocytic cells in PC of old mice abrogates the induction of 4-BBL expression in i.p. injected congenic young mouse
GFP+ B cells. Individual mouse results (dots) and mean value (lines) of five to six representative mice per group. This experiment was reproduced twice. (D)
Unlike young (Young-Mo), elderly human PB monocytes (Old-Mo) also convert young human B cells into 4BL cells. The induction was lost if B cells were
pretreated with Btk or SYK inhibitors. Mean6 SEM of 4-1BBL+ in eFluor 450-labeled B cells treated with myeloid cells from three young and five elderly
people. *p , 0.05, **p , 0.01, ***p , 0.005.
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B cells of young humans with PB monocytes of young or elderly
humans. As in mice, only elderly human monocytes strongly in-
duced expression of 4-1BBL in B cells (p , 0.05; Fig. 3D), and
this induction was lost if human B cells were pretreated with Btk
and Syk inhibitors (p , 0.05, Btk or Syk versus Mock; Fig. 3D).
4BL cells upregulate mTNF-a via signaling with 4-1BBL
Because the conversion of 4BL cells leads to upregulation ofmTNF-a
(Fig. 1A, 1B), we next wanted to understand the mechanism of
this induction. Macrophages require 4-1BBL signaling to sustain
expression of TNF-a (49), suggesting that a similar mechanism
could also be used in 4BL cells. To test this possibility, we stim-
ulated B cells fromWTand 4-1BBL KO mice with anti-BCR/CD40
Ab alone or together with plate-bound 4-1BB–Fc protein [4-1BBL
agonist (49)] or with a nonspecific B cell mitogen, LPS (50). Al-
though LPS or anti-IgM/CD40 Ab induced comparable expres-
sion of TNF-a in B cells regardless of the presence or absence of
4-1BBL (i.e., WT and 4-1BBL KO; Fig. 4A), a combined treatment
with BCR/CD40 Ab and 4-1BB–Fc strongly upregulated TNF-a in
WT B cells, but not in 4-1BBL KO B cells (Fig. 4A). Hence BCR/
CD40 signaling initiates expression of 4-1BBL and TNF-a (as also
discussed for Fig. 3B, 3C); then 4-1BBL is needed to further up-
regulate TNF-a in 4BL cells upon engagement with 4-1BB.
Because TNF-a can be involved in expression of GrB (51), we
evaluated expression of its receptors on CD8+ T cells. Unlike
TNFR1, TNFR2 was upregulated on GrB+CD8+ cells of aging
mice and humans (Fig. 4B). Thus, considering high levels of
expression of its ligand mTNF-a on 4BL cells (Fig. 1A, 1B), we
next tested whether the mTNF-a/TNFR2 axis is used to induce
expression of GrB in CD8+ T cells. First, we included TNF-a
neutralizing Ab or control IgG1 in our in vitro GrB+CD8+ T cell
induction assay with 4BL cells, and we observed that the de-
pletion of TNF-a significantly retarded the induction of GrB
expression in CD8+ T cells (Fig. 4C). The induction of GrB+
CD8+ T cells was also markedly retarded if we used 4BL cells
from TNF-a KO mice (Fig. 4D). Moreover, WT 4BL cells failed
to efficiently induce expression of GrB in CD8+ T cells from
TNFR2 KO mice (Fig. 4E), whereas the induction was unim-
paired in TNFR1 KO CD8+ T cells (Fig. 4E). Similarly for hu-
man cells, TNFR2 or TNF-a neutralizing Abs also abrogated the
induction of GrB+CD8+ T cells in an MLR assay using elderly
human 4BL cells (Fig. 4F). Because the mTNF-a/TNFR2 axis
probably requires a cell contact, we also cultured 4BL cells with
CD8+ T cells either in the same well or separated with a porous
membrane in transwell assay. The separation of the two cells
completely abrogated the induction of GrB+CD8+ T cells
FIGURE 4. 4BL cells induce GrB+CD8+ T cells using TNF-a. (A) The 4-1BBL expression in B cells induced with anti-mouse IgM/anti-mouse CD40 Ab is
further upregulated upon overnight stimulation with plate-bound 4-1BB:Fc protein, but not control human IgG1 (HuIgG1, 10 mg/ml). Upregulation is lost in 4-BBL
KO B cells. Control cells were treated with LPS (1 mg/ml) as a nonspecific stimulator. (B) Representative histogram shows that TNFR2 is mostly expressed on GrB+
CD8+ T cells. Thick and thin lines are for GrB+ and GrB2CD8+ T cells, respectively. Murine (C–E and G) and human (F) 4BL cells lose the ability to induce GrB+
CD8+ T cells in the presence of TNF-a neutralizing Ab (C and F, 5 mg/ml), anti-TNFR2 Ab (F, 10 mg/ml), or if B cells are TNF-a KO (D) or T cells are from
TNFR2 KO, but not TNFR1 KO, mice (E). No GrB+CD8+ T cells were induced if B cells and T cells were physically separated in a transwell assay (G). Frequency
mean 6 SEM of GrB+CD8+ T cells of a representative experiment repeated at least three times with two to four mice and human cells per group. *p , 0.05.
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(Fig. 4G). Together, these data demonstrate that BCR/CD40
signaling induces expression of 4-1BBL and mTNF-a on
4BL cells. Furthermore, upon activation of 4-1BBL, mTNF-a is
further upregulated to induce GrB+CD8+ T cells by targeting
TNFR2.
4BL cells upregulate TNFR2 in CD8+ T cells by targeting
4-1BB
Next, we wanted to understand how CD8+ T cells upregulate
TNFR2. Because TCR stimulation induces expression of
4-1BB (32, 33, 36), we tested whether it can also upregulate
TNFR2. Indeed, CD8+ T cells stimulated with anti-CD3 or
anti-CD3/CD28 Ab not only induced expression of 4-1BB
(Supplemental Fig. 3C) but also TNFR2 (Fig. 5A–D). How-
ever, expression of TNFR2 was further and considerably up-
regulated if the stimulation also contained agonistic 4-1BB Ab
(3H3; Fig. 5A, 5B). Because treatment with 3H3 alone did not
induce expression of TNFR2 (Fig. 5B) (presumably because of
low levels of 4-1BB on resting T cells; Supplemental Fig. 3C)
(33), these results suggest that activated T cells first need to
induce expression of 4-1BB, which upon receiving signaling
from 4-BBL expressed on 4BL cells can further upregulate
expression of TNFR2. In support of this model, the anti-CD3/
CD28 Ab–induced expression of TNFR2 in CD8+ T cells
was markedly augmented upon coculture with sort-purified
4-1BBL+, but not 4-1BB2, B cells of old mice (4BL and B cells,
respectively; Fig. 5C). However, if CD8+ T cells were from 4-1BB
KO mice, the 4BL cell–induced upregulation of TNFR2 was lost,
because its expression failed to increase beyond the levels
induced by anti-CD3/CD28 Ab stimulation alone (Fig. 5C).
Thus, the induction of TNFR2 expression in CD8+ T cells is
bimodal because its expression induced via TCR signaling is
further upregulated upon 4-1BB signaling induced by 4BL
cells. Because 4-1BB can signal via both the canonical and the
noncanonical NF-kB pathway (52), we also compared the in-
duction of TNFR2 in CD8+ T cells from mice deficient in clas-
sical (p50) and noncanonical (p52) NF-kB. Even though 4BL
cells in the presence of anti-CD3 Ab upregulated TNFR2 in p50
KO CD8+ T cells as efficiently as in WT T cells (Fig. 5D), they
failed to do so in p52 KO T cells (Fig. 5D) as if the T cells were
4-1BB KO (Fig. 5C, 5D). Hence 4BL cells use 4-1BBL to up-
regulate expression of TNFR2 in CD8+ T cells via inducing
noncanonical NF-kB signaling from 4-1BB. As discussed earlier,
the TNFR2 is then targeted to induce expression of GrB in
CD8+ T cells. Indeed, the TNFR2 upregulation mirrored the induc-
tion of GrB+CD8+ T cells; that is, the induction of GrB expression
in p52 KO (Fig. 5E) and 4-1BB KO (Fig. 5F) CD8+ T cells was
reduced to the levels induced by anti-CD3 Ab stimulation alone
despite the presence of old mouse 4BL cells. Notably, GrB in-
duction was also reduced in p50 KO CD8+ T cells (Fig. 5E),
FIGURE 5. 4BL cells upregulate TNFR2 in CD8+ T cells via the 4-1BB/4-1BBL axis. Although TNFR2 is induced on resting human (A) and murine (B)
CD8+ T cells after stimulation with anti-CD3/CD28 Ab (thin line) for 24 h, it is further upregulated upon 4-1BB engagement [anti-CD3/CD28/4-1BBL Ab
beads, thick line in (A), and anti-CD3/CD28 Ab with 3H3 Ab, 5 mg/ml in (B)]. Dotted line is for nonstimulated T cells. Unlike 4-1BBL2B cells (B cell, C),
aging 4BL cells induce TNFR2 in CD8+ T cells (C and D). Upregulation is lost in T cells from 4-1BB KO (C and D) and p52, but not p50, NF-kB KO (D) mice.
Before mixing with B cells, T cells were pretreated with anti-CD3 Ab (1.5 mg/ml) for 24 h to upregulate 4-1BB. CD8+ cells shown in (C) and (D) also express
GrB after 5-d culture (E and F). Mean 6 SEM of a representative experiment repeated at least twice with three to four mice per group. *p , 0.05.
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suggesting that, unlike TNFR2, its expression requires canonical
NF-kB (53).
Myeloid cells enhance costimulatory function of 4BL cells via IFN-g
Interestingly, besides being high expressers of 4-1BBL, MHC
class-I and CD86 (30), as well as mTNF-a, 4BL cells also
expressed IFN-gR1 (Fig. 6A). Its expression appears to also de-
pend on BCR/CD40 signaling, because resting murine and human
B cells markedly upregulated IFN-gR1 upon anti-IgM/CD40 Ab
stimulation (Fig. 6B). Because IFN-g is a potential inducer of
CD86 (54), we hypothesized that 4BL cells probably enhance
their T cell costimulatory functions by receiving IFN-g expressed
FIGURE 6. Myeloid cells also enhance the costimulatory function of 4BL cells via IFN-g. (A) Although human and murine 4BL cells mostly express IFN-gR1
(A, thick line), both 4-BBL KO and WT B cells upregulate its expression upon anti-IgM/CD40 stimulation (B, red and black thick lines). IFN-gR1 KO 4BL cells
less efficiently induce GrB+CD8+ T cells in vitro (C). Unlike 4-BBL that is induced on both IFN-gR KO and WT CD5+ B cells stimulated with myeloid cells of
old mice (Old-M) but not young mice (Young-M, D), CD86 requires IFN-g signaling, because it was not induced on IFN-gR1 KO B (F). Compared with WT 4BL
cells, 4BL cells from ARE-Del mice induce a higher frequency of GrB+CD8+ T cells (E). Mean 6 SEM of a representative experiment repeated at least twice in
triplicate experiments with three to four mice per group is shown. PC macrophages of old mice in vivo induce CD86 (G). B1a cells from young GFP+ mice (G)
were i.p. injected into congenic young and old mice pretreated with control liposome or clodronate liposomes (G), as in Fig. 3C. (H) eFluor 450–labeled B cells
from WTor IFN-gR1 KO mice were i.p. injected into old WT mice. Frequency of CD86+ in GFP+ B1a (G) or eFlur450+B1a (H) from individual mice (dots) and
mean value (lines) of a representative five to six mice per group experiment repeated twice are shown. Ex vivo, myeloid cells of young ARE-Del mice (B+ARE-
Del-M) also strongly upregulate CD86 on B cells of young WT mice compared with WT myeloid cells (B+WT-M, I). *p , 0.05.
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in aging CD11b+myeloid cells (Supplemental Fig. 2E, 2F). In
concordance, 4BL cells from IFN-gR1 KO mice failed to effi-
ciently induce the generation of GrB+CD8+ T cells in vitro (Fig.
6C). Conversely, the presence of blocking CD86 Ab (but not
control Ab) was sufficient to abrogate the induction of GrB+
CD8+ T cells with WT 4BL cells (Supplemental Fig. 4A). Although
IFN-g alone upregulated CD86 on resting B cells (Supplemental
Fig. 4B), it was not sufficient to convert B cells into 4BL cells.
IFN-g and IFN-gR expression status (IFN-g KO and IFN-gR1
KO) did not affect the low frequency of 4BL cells present in
young mice (Supplemental Fig. 4C–E, and B-alone in Fig. 6D),
which is usually around 5% of B cells (30). Similarly, the pro-
portion of 4BL cells was not increased in ARE-Del mice
(Supplemental Fig. 4F), which constitutively express IFN-g (39).
Although B cells of ARE-Del mice demonstrate highly upregu-
lated CD86 compared with WT mice (Supplemental Fig. 4G),
their sort-purified 4-1BBL2B cells failed to induce GrB+
CD8+ T cells stimulated with anti-CD3 Ab (Fig. 6E) despite their
chronic exposure to IFN-g. In contrast, ARE-Del 4-1BBL+ (4BL
cells) markedly induced GrB+CD8+ T cells with a significantly
higher potency than WT 4BL cells (p , 0.05; Fig. 6E). Hence
these results suggest that 4BL cells use IFN-gR1 to upregulate
CD86, and thereby contribute to the generation of GrB+CD8+
T cells.
To test the role of myeloid cells in this process, we cocultured
purified CD5+ B cells (B-alone) from young WT and IFN-gR1 KO
mice with congenic PC Young-M and Old-M cells. Although
Old-M upregulated 4-1BBL on both WT and IFN-gR1 KO
B cells (Figs. 3, 6D), they failed to induce CD86 in IFN-gR1 KO
B cells (Fig. 6F, Supplemental Fig. 4E). Young mouse B cells also
significantly upregulated CD86 upon injection into PC of con-
genic and macrophage-sufficient old mice (Fig. 6G), but failed to
do so in old mice depleted of macrophages (Fig. 6G) or if B cells
were from IFN-gR1 KO mice (Fig. 6H). Control B cells both
in vitro and in vivo exposed to Young-M cells did not induce
expression of CD86 and 4-1BBL (see B-alone or mock with B +
Young-M, Fig. 6D, 6F, Supplemental Fig. 4E, and Young in Fig.
6G). Furthermore, CD11b+ myeloid cells from PC of young ARE-
Del mice [which constitutively express IFN-g (39)] also strongly
upregulated CD86 upon their in vitro coculture, whereas WT
CD11b+ cells of young mice failed to do so (Fig. 6I), probably
accounting for the enhanced ability of 4-1BBL+ B cells from ARE-
Del mice to induce GrB+CD8+ T cells (Fig. 6E). Together, these
results indicate that aging myeloid cells, such as macrophages, use
the IFN-g/IFN-gR1 signaling axis to enhance the costimulatory
function of 4BL cells by upregulating CD86 (Fig. 7).
Discussion
Aging significantly dysregulates the function and distribution of
B cells in the circulation (15–18), resulting in impaired humoral
responses to new Ags and vaccines in the elderly (55) (see reviews
in Refs. 1, 2). We recently reported that elderly humans, ma-
caques, and mice accumulate 4-1BBL+ B cells (4BL cells) of
unknown origin (30). They phenotypically and functionally
differ from other B cells enriched in aging, such as mature and
Ag-experienced memory B2 cells of mammals (15–18) and
exhausted mature B2 cells (ABCs) in mice (29). In this study, we
demonstrate that, at least in mice, 4BL cells are B1a cells con-
verted upon aging, whereas in human PB they appear to be
memory CD432CD27+ B cells. The failure to link 4BL cells with
human memory CD43+CD27 + B cells that contain B1 cells (27)
could be because of reduced CD43 expression in aging or the
species difference. Although aging is not known to affect the
function of innate B1 cells (11, 20, 21), it increases the numbers of
both B1a cells (as well as B2 cells) in PC of mice (11), presum-
ably because of their enhanced longevity (13), self-renewal ca-
pabilities (21), and homing in response to elevated production of
CXCL13 (56–58). Aging B1a cells increase 3-fold in mice (21,
59) and, being CXCR5High, infiltrate into spleen and PC with a
higher efficiency than B2 cells (56–58). Functionally, aging B1
cells are implicated in autoimmune diseases, such as Sjögren
syndrome in humans (60) and lupus erythematosus in mice (61),
and are primarily considered the producers of natural Abs, me-
diators of tissue homeostasis, and involved in the clearance of
apoptotic cells (62). In contrast, our data indicate that aging dra-
matically affects the function of B1a cells, because they lose
FIGURE 7. Summary schema. Aging CD11b+ myeloid cells initiate a chain of events that convert B1a cells into 4BL cells and concurrently induce GrB+
CD8+ T cells. First, they convert B1a cells into 4BL cells by inducing expression of 4-1BBL, mTNF-a, and IFN-gR (1). Then 4BL cells further upregulate
mTNF-a and CD86 via activating 4-1BBL (2) and IFN-gR1 (3) signaling from 4-1BB and IFN-g provided by aging myeloid cells, respectively. 4BL cells
activate CD8+ T cells to express 4-1BB (4) and TNFR2 (5). This activation enables 4BL cells to trigger noncanonical NF-kB signaling from 4-1BB and
further increase expression of TNFR2 on CD8+ T cells (6). The TNFR2 is targeted with mTNF-a to induce expression of GrB in CD8+ T cells while
providing costimulation with CD86 (7).
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tumor-supporting (43) and possibly immunosuppressive activities
but gain a new property: the induction of GrB+CD8+ T cells. For
example, whereas young B1a cells strongly enhance the growth
of B16 melanoma in congenic B cell–deficient mice, aging B1a
cells fail to do so. Instead, they retard tumor growth by inducing
antitumor GrB+CD8+ T cells, the function of which we previ-
ously reported for 4BL cells in old mice with poorly immuno-
genic tumors and in breast cancer patients after autologous
hematopoietic stem transplantation (30). Thus, aging renders
B1a cells/4BL cells into APCs that can uptake endogenous
Ags in vivo (e.g., B16 melanoma or i.p. injected OVA protein)
and induce Ag-specific CD8+ T cell responses such as TCR-
transgenic CD8+ T cells from pmel and OT-1 mice, respectively.
This is in line with the fact that 4BL cells highly express an array
of surface molecules needed for the induction of CD8+ T cells,
including MHC class-I, CD86, CD40, and 4-1BBL (30).
In our previous report, we hypothesized that the generation of
4BL cells is induced by extrinsic factors, because these cells also
accumulate in cancer patients after autologous hematopoietic
stem transplantation and their reappearance after B cell depletion
in Old-restored mice was significantly delayed compared with the
rest of the B cells (30). In this study, we experimentally confirm
this hypothesis by demonstrating the importance of aging mye-
loid cells, such as human monocytes and murine PC macro-
phages, in the conversion of 4BL cells. This is in line with a
plethora of changes reported for monocytes and macrophages
upon aging in humans and rodents. For example, old rats enrich
for CD11b+ monocytes expressing IFN-g (63), whereas elderly
human PB accumulates so-called intermediate and nonclassical
monocytes producing high levels of TNF-a (8). Aging also im-
pairs phagocytosis of myeloid cells, such as human neutrophils
and CD14+ monocytes and murine PC macrophages (8, 11), and
the responses of monocytes and macrophages to IFN-g and TLR
stimulations (64–66). We also found that old mice show an in-
crease in CD11b+ myeloid cells and macrophages expressing
IFN-g and CD40L. Importantly, our in vitro and in vivo exper-
iments indicate that aging mouse PC CD11b+ myeloid cells can
directly convert young mouse B1 cells into 4BL cells. Because
control myeloid cells from young mice or old mice depleted of
phagocytic cells such as macrophages failed to do so, we con-
clude that the conversion is primarily mediated by aging mac-
rophages. In humans, PB monocytes of the elderly appear to be
the inducers of 4BL cells. Thus, by corroborating the importance
of cross talk between myeloid cells/macrophages and B cells
(67–69), our data suggest that the dysregulation of macro-
phages in the elderly can initiate a chain of events including the
conversion of B1a cells into 4BL cells and concurrent induction
of cytolytic CD8+ T cells, as summarized in Fig. 7. First, they
trigger BCR and CD40 signaling, and thereby induce expression
of 4-1BBL, mTNF-a, and IFN-gR1 in B1a cells, converting them
into 4BL cells (step 1, Fig. 7). This initial step can be abrogated
by blocking BCR or CD40 signaling, indicating the importance
of these pathways in the conversion of 4BL cells, as well as in
the development and function of B1a cells (25, 48). Because
human and murine monocytes and macrophages express CD40L
(70) and CD40L+CD11b+ myeloid cells that are enriched in PC
of aging mice, they could provide CD40L to activate CD40 on
B1a cells. In contrast, we do not know the mechanism of the
BCR signaling. Because macrophages can stimulate BCR during
exchange of Ags (46, 47) via FcgRIIB-captured and recycled
immune complexes (71), we can only speculate that myeloid
cells of aging subjects activate B1a cells by using autoreactive
Ab that is increased upon aging (72). As a result, 4BL cells
express 4-1BBL to further upregulate expression of mTNF-a and
IFN-gR1 upon engagement with 4-1BB (step 2, Fig. 7). This is
consistent with the fact that signaling of 4-1BBL is required for
sustained production of TNF-a in macrophages (49, 73) and that
its receptor is also expressed on myeloid cells such as splenic
DCs (32). By expressing IFN-gR1, 4BL cells also upregulate
CD86 in response to IFN-g (step 3, Fig. 7). Using neutralizing
Ab or cells with impaired expressions of IFN-g or IFN-gR1, we
demonstrate that aging CD11b+ myeloid cells and macrophages
provide IFN-g, although in vivo it can probably be supplied by
IFN-g–producing cells such as Th1 T cells and NK cells. In
addition, considering its importance in MHC class-I expression
and Ag presentation (74), IFN-g is probably responsible for the
enhanced expression of MHC class-I on 4BL cells (30). Thus,
aging myeloid cells induce high levels of expression of 4-BBL,
mTNF-a, CD86, and MHC-I on B1a cells. As a result, the ac-
tivated B1a cells/4BL cells become APCs that induce Ag-specific
GrB+CD8+ T cell responses requiring the 4-1BBL/4-1BB signaling
axis (30). First, aging B1a cells induce expression of 4-1BB (step 4)
and TNFR2 (step 5, Fig. 7) in CD8+ T cells. Then they target 4-1BB
via 4-1BBL to further upregulate expression of TNFR2 in
CD8+ T cells (step 6, Fig. 7). Confirming the use of the noncanonical
NF-kB signaling by 4-1BB (52), 4BL cells failed to upregulate
TNFR2 in CD8+ T cells deficient in the noncanonical, but not ca-
nonical, NF-kB signaling pathway. Then, using mTNF-a, 4BL cells
target TNFR2 and induce expression of GrB in CD8+ T cells (step 7,
Fig. 7), while providing costimulation with CD86. In summary, our
data suggest that aging converts B1a cells into potentially pathogenic
and autoimmune 4BL cells via dysregulation of the myeloid cell
compartment.
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S Fig1. In vivo 4BL cells induction. (A) The 4BL cell conversion of splenic and peritoneal cavity (PC) B 
cells of young GFP+ mice upon their i.p. (A) or i.v. (B) injection into congenic young or old C57BL/6 mice.  
Shown, a representative result (mean ± SEM) of 3 independent experiments (n ≥ 4 mice/group/experiment). 
(C) Representative plot showing the expression of 4-BBL and TNFα in PC B-cell subsets (CD5-, pro-B10, 
and B1a B cells) of young and old mice (i). Compared to young mice, B1a cells of old mice express higher 
levels of mTNFα  (ii). Shown, a representative result (mean ± SEM) of 4 independent experiments (n ≥ 
4mice/group/experiment). (D) B cells do not proliferate in the PC of young (black line) or old (red line) mice 
upon their injection. Shown is a representative result (mean ± SEM) of 2 independent experiments (n ≥ 
4mice/group/experiment). (E) Sort-purified pro-B10 and B1a cells, as well as unsorted total B cells, from PC 
of old (light grey) and young (dark) mice exhibit a comparable ability to induce proliferation of CD8+ T cells 
stimulated with anti-CD3 Ab.  Shown, a representative result (mean ± SEM) of 3 independent experiments 
performed in triplicates. (F) 4-1BBL is highly expressed in memory and B1 cells of elderly humans. Shown is 
a representative result of 11 young (41 ± 7.2 years old) and 19 elderly donors (79 ± 6.45 years old), where we 
compared expression of 4-BBL in memory, naïve, activated CD69+B cells, plasmablasts, and B1 cells. (G) 
Elderly human memory CD27+ B-cells strongly induce GrB+CD8+ T cells in vitro, while CD43+B cells and 
CD27- B cells failed to do so. Shown is a representative result (mean ± SEM) of 3 independent experiments 
(n ≥ 2 human cells/group/experiment). (H) Adoptively transferred sB1a cells of old mice, but not FOB or 
young mouse sB1a cells, increase frequency of GrB+CD8+ T cells in B-cell deficient JHT mice with B16 
melanoma. Shown is the mean (%) ± SEM of GrB in CD8+T cells in spleens (i) and LN (ii) at day 20 post 
tumor challenge. The experiment was reproduced twice with 4-5 mice/group. P-value significance is shown 





































































































































































































S Fig2. PC myeloid cells and macrophages are dysregulated in old mice, as shown 
by enrichment for  CD40L, IL10, and IFNγ –expressing CD11b+ PC myeloid cells 
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S Fig3. Aging myeloid cells induce 4BL cells (A,B). CD11b+ myeloid cells isolated 
from PC of young and old mice (depleted of B cells, T cells, and NK cells with CD19-
PE+CD3-PE + anti-PE MicroBeads and DX5-PE + anti-PE MicroBeads, which 
yielded >80% enrichment in CD11b+ cells, (A) were cultured with eFluor® 450-
labeled B cells (from naïve young mice) at 1:1 ratio (B) for 24 h. As shown in a 
representative experiment performed ≥ 4 times (B), B cells did not proliferate. (C) 
Murine CD8+ T cells express 4-1BB upon CD3/CD28 activation. Murine CD8+ T 
cells were activated with 1.5 μg/ml of soluble anti-CD3 Ab + 1.5 μg/ml of soluble 
anti-CD28 for 24 h. Shown, a representative result (mean ± SEM) of 2 independent 
experiments performed in triplicates. P-value significance is shown as *p<0.05.  
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S Fig4. Importance of IFN provided by myeloid cells in induction of 4BL cells. (A) 4BL cells use 
CD86 in induction of GrB+CD8+ T cells, as it was lost in the presence of an anti-CD86 blocking Ab. (B) 
Young mouse splenic B cells up-regulate CD86 upon treatment with IFNγ (100 U/ml,  24 h). (C, D) 
Expression of 4-BBL in splenic and PC B cells is not affected by the loss of IFN signaling, such as in 
IFNR1 KO or IFN KO mice. (E) Despite the loss of IFNγR (light grey), B cells up-regulate 4-1BBL in 
response to aging myeloid cells of mice (Old-M vs Young-M) as well as WT B cells (dark bars). (F) 
Compared to WT mice, B cells from young ARE-Del mice, which constitutively produce IFN, express 
comparable levels of 4-1BBL in splenic and PC B cells. (G) However, only ARE-Del mouse B cells 
express higher levels of CD86. Shown is a representative result (mean ± SEM) of 3 independent 
experiments (n ≥ 3 mice/group) performed in triplicates. P-value significance is shown as *p<0.05 and NS 
= not statistically significant. 
 
